FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975293480> ?p ?o ?g. }

• W2975293480 endingPage "491" @default.
• W2975293480 startingPage "491" @default.
• W2975293480 abstract "491 Objectives: Glioma constitutes approximately 30% of the CNS tumors and approximately 80% of all the malignant brain tumors. The median survival in high grade glioma (GBM) is 15 months and the 5-year survival is approximately 10%. Magnetic resonance imaging (MRI) is the most commonly used procedure in the follow-up of such patients. However, molecular imaging (SPECT, PET) is often required for the tumor characterization and detection of active recurrent/residual disease. The currently available PET tracers i.e. 18F-FET and 11C-methionine have proven high diagnostic efficacy in GBM. Nevertheless, the clinical applications of 68Ga-labeled compounds are on the rise as this radionuclide has the potential for an on-demand production via generator technologies for routine production of various PET tracers without the need for expensive cyclotron operations. A strong association has been reported between CXCR4 chemokine receptor, with the development of an invasive phenotype in malignant GBM and eventually resulting in poor prognosis. Methods: In this study, we used 68Ga-Pentixafor PET/CT for quantitative imaging of CXCR4 expression in GBM patients having clinical suspicion of recurrent/residual disease. Fourteen patients (8M: 6F; Mean Age- 51 ±12 yrs) with histopathologically proven GBM disease on surgical excised samples and with clinical suspicion of recurrent/residual GBM disease during post surgical follow-up were recruited prospectively. All the patients received radical radiotherapy (54.0-60.0 Gy) after surgery with or without concurrent temozolomide as indicated and underwent 68Ga-Pentixafor PET/CT and conventional ceMRI of the brain. About 110-150 MBq radioactivity of freshly prepared 68Ga-Pentixafor (synthesized by using Scintomics Germany, automated chemistry module, procured under DST-FIST Project Funding) was administered intravenously. Regional Brain CT (140Kv, 200mAs, Pitch 0.625:1, Slice thickness 2.5 mm) followed by PET acquisition (single bed position of 8min) at 1-hour post injection. Data was reconstructed using iterative method (2 iterations, 20 sub-sets) and interpreted both visually and semi-quantitatively. Results: 68Ga-Pentixafor PET/CT findings with focally increased uptake of the radiotracer were interpreted as positive for recurrent/residual disease in 13/14 patients. The mean SUVmax value in these patients (n=13) was 5.25 ± 2.07 (range: 2.71 -9.69). PET/CT findings were concurrent with MRI findings in all the 14 patients. A representative 68Ga-Pentixafor PET image in a patient (58 yrs, Female) with recurrent tumor in central primary GBM disease showing intense uptake of the radiotracer (SUVmax=7.9) is presented in Figure-1. The only (1/14) patient who had no focal uptake anywhere in the brain on 68Ga-Pentixafor PET was interpreted as negative for any residual/recurrent disease. The ceMRI finding in this patient was also negative and reported as gliosis. Conclusions: It has been proven in few recent preclinical and clinical studies (mainly multiple myeloma, isolated solid tumors including lung cancer) that 68Ga-Pentixafor uptake is tied up specifically to CXCR 4 expression. The results of this preliminary study demonstrate that 68Ga-Pentixafor PET imaging in GBM (know to have high CXCR4 expression) is viewed to open-up new theranostics applications (with beta and alpha radionuclides) for long term survival benefits. However, the diagnostic utility of this tracer needs to be validated in a large cohort of patients through multi-centric trials." @default.
• W2975293480 created "2019-10-03" @default.
• W2975293480 creator A5003893345 @default.
• W2975293480 creator A5024110054 @default.
• W2975293480 creator A5036410096 @default.
• W2975293480 creator A5059908678 @default.
• W2975293480 creator A5063772320 @default.
• W2975293480 creator A5074615432 @default.
• W2975293480 creator A5080640691 @default.
• W2975293480 date "2019-05-01" @default.
• W2975293480 modified "2023-09-22" @default.
• W2975293480 title "68Ga-Pentixafor PET/CT offers high contrast image for the detection of CXCR4 expression in recurrent glioma." @default.
• W2975293480 hasPublicationYear "2019" @default.
• W2975293480 type Work @default.
• W2975293480 sameAs 2975293480 @default.
• W2975293480 citedByCount "0" @default.
• W2975293480 crossrefType "journal-article" @default.
• W2975293480 hasAuthorship W2975293480A5003893345 @default.
• W2975293480 hasAuthorship W2975293480A5024110054 @default.
• W2975293480 hasAuthorship W2975293480A5036410096 @default.
• W2975293480 hasAuthorship W2975293480A5059908678 @default.
• W2975293480 hasAuthorship W2975293480A5063772320 @default.
• W2975293480 hasAuthorship W2975293480A5074615432 @default.
• W2975293480 hasAuthorship W2975293480A5080640691 @default.
• W2975293480 hasConcept C126322002 @default.
• W2975293480 hasConcept C126838900 @default.
• W2975293480 hasConcept C129470790 @default.
• W2975293480 hasConcept C13373296 @default.
• W2975293480 hasConcept C142724271 @default.
• W2975293480 hasConcept C143409427 @default.
• W2975293480 hasConcept C170493617 @default.
• W2975293480 hasConcept C2777389519 @default.
• W2975293480 hasConcept C2778227246 @default.
• W2975293480 hasConcept C2780103909 @default.
• W2975293480 hasConcept C2989005 @default.
• W2975293480 hasConcept C502942594 @default.
• W2975293480 hasConcept C509974204 @default.
• W2975293480 hasConcept C71924100 @default.
• W2975293480 hasConceptScore W2975293480C126322002 @default.
• W2975293480 hasConceptScore W2975293480C126838900 @default.
• W2975293480 hasConceptScore W2975293480C129470790 @default.
• W2975293480 hasConceptScore W2975293480C13373296 @default.
• W2975293480 hasConceptScore W2975293480C142724271 @default.
• W2975293480 hasConceptScore W2975293480C143409427 @default.
• W2975293480 hasConceptScore W2975293480C170493617 @default.
• W2975293480 hasConceptScore W2975293480C2777389519 @default.
• W2975293480 hasConceptScore W2975293480C2778227246 @default.
• W2975293480 hasConceptScore W2975293480C2780103909 @default.
• W2975293480 hasConceptScore W2975293480C2989005 @default.
• W2975293480 hasConceptScore W2975293480C502942594 @default.
• W2975293480 hasConceptScore W2975293480C509974204 @default.
• W2975293480 hasConceptScore W2975293480C71924100 @default.
• W2975293480 hasLocation W29752934801 @default.
• W2975293480 hasOpenAccess W2975293480 @default.
• W2975293480 hasPrimaryLocation W29752934801 @default.
• W2975293480 hasRelatedWork W2119868868 @default.
• W2975293480 hasRelatedWork W2235948843 @default.
• W2975293480 hasRelatedWork W2394887082 @default.
• W2975293480 hasRelatedWork W2463188066 @default.
• W2975293480 hasRelatedWork W2525904487 @default.
• W2975293480 hasRelatedWork W2532326493 @default.
• W2975293480 hasRelatedWork W2591970452 @default.
• W2975293480 hasRelatedWork W2889100646 @default.
• W2975293480 hasRelatedWork W2966400779 @default.
• W2975293480 hasRelatedWork W2982320676 @default.
• W2975293480 hasRelatedWork W2996367304 @default.
• W2975293480 hasRelatedWork W3032613570 @default.
• W2975293480 hasRelatedWork W3042017449 @default.
• W2975293480 hasRelatedWork W3094601468 @default.
• W2975293480 hasRelatedWork W3111749908 @default.
• W2975293480 hasRelatedWork W3128462562 @default.
• W2975293480 hasRelatedWork W3135033651 @default.
• W2975293480 hasRelatedWork W3205697301 @default.
• W2975293480 hasRelatedWork W46276704 @default.
• W2975293480 hasRelatedWork W187170147 @default.
• W2975293480 hasVolume "60" @default.
• W2975293480 isParatext "false" @default.
• W2975293480 isRetracted "false" @default.
• W2975293480 magId "2975293480" @default.
• W2975293480 workType "article" @default.